Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 4.04M shares outstanding
USEloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation.
Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons.
The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations.
In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis.
The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Daniel Geffken, M.B.A.
Interim Chief Financial Officer
Sumit Aggarwal
President, Chief Executive Officer & Director
Sumit Aggarwal, M.B.A.
President and Chief Executive Officer
Tomer Kariv
Chairman of the Board
Employees
10
Country
US
Sector
Healthcare
Website
eloxxpharma.com
Loading congressional disclosures…
based on 4.04M shares outstanding
US30d Avg
23.92K
60d Avg
34.49K
90d Avg
44.78K
